Clinical implications of the new biology in the development of melanoma vaccines

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

1994 • 5,204 citations

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1991 • 3,493 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993 • 2,828 citations

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1998 • 2,373 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

The National Cancer Data Base report on cutaneous and noncutaneous melanoma

1998 • 1,549 citations

A p16 ^INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

1995 • 1,147 citations

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1995 • 1,097 citations

Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

1994 • 991 citations

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1993 • 986 citations

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1990 • 926 citations

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.

1993 • 888 citations

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

1994 • 850 citations

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.

1996 • 746 citations

Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4

1991 • 733 citations

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

1992 • 694 citations

BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes

1995 • 598 citations

A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.

1995 • 591 citations

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

1994 • 522 citations

Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.

1989 • 511 citations

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2

1998 • 480 citations

Immunological factors which influence response to immunotherapy in malignant melanoma.

1970 • 462 citations

Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

1992 • 410 citations

Demonstration of antibodies against human malignant melanoma by immunofluorescence.

1968 • 390 citations

A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3

1994 • 379 citations

Immunotherapy of malignancy by in vivo gene transfer into tumors.

1993 • 320 citations

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1990 • 300 citations

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

1995 • 282 citations

A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous Melanoma

1982 • 282 citations

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

1995 • 264 citations

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.

1996 • 259 citations

Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

1982 • 242 citations

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

1988 • 239 citations

Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.

1995 • 237 citations

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA–liposome complexes

1996 • 237 citations

Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.

1992 • 232 citations

A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside.

1984 • 222 citations

Retroviral transduction of human dendritic cells with a tumor-associated antigen gene.

1996 • 218 citations

Lysis of Autologous Melanoma Cells by Tumor*Infiltrating Lymphocytes: Association With Clinical Response

1991 • 196 citations

Active-specific immunotherapy for melanoma.

1990 • 186 citations

Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data from a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial

1998 • 183 citations

Ganglioside GM2 as a human tumor antigen (OFA-I-1).

1983 • 174 citations

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.

1997 • 167 citations

A Pathogenic Role of Th2 Cells and Their Cytokine Products on the Pulmonary Metastasis of Murine B16 Melanoma

1998 • 166 citations

Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.

1995 • 161 citations

A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes

1996 • 135 citations

Vaccine therapy for malignant melanoma

1996 • 133 citations

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

1997 • 128 citations

Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line

1995 • 128 citations

Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1).

1996 • 121 citations

Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.

1997 • 119 citations

IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.

1995 • 117 citations

A phase I clinical trial of immunotherapy with interferon-? gene-modified autologous melanoma cells

1997 • 108 citations

Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.

1996 • 106 citations

Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.

1997 • 104 citations

A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy

1997 • 101 citations

Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates Rationale, Results, and Possible Mechanisms of Actiona

1993 • 97 citations

Getting to the Source: Dendritic Cells as Therapeutic Reagents for the Treatment of Patients With Cancer

1997 • 95 citations

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.

1991 • 81 citations

Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial

1981 • 79 citations

A Phase I Study of Vaccination with Autologous, Irradiated Melanoma Cells Engineered to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor. Dana-Farber Cancer Institute, Boston, Massachusetts

1997 • 77 citations

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.

1991 • 76 citations

Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.

1996 • 72 citations

Active Immunotherapy of Human Melanoma Exploiting the Immunopotentiating Effects of Cyclophosphamide

1988 • 63 citations

T‐Cell Clones that react against Autologous Human Tumors

1990 • 61 citations

Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression.

1998 • 61 citations

Generation of T-Cells Reactive to the Poorly Immunogenic B16-BL6 Melanoma with Efficacy in the Treatment of Spontaneous Metastases

1993 • 59 citations

Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model

1996 • 59 citations

Positive Relationship of Clinical and Serologic Responses to Vaccinia Melanoma Oncolysate

1987 • 55 citations

Adjuvant therapy for melanoma

1997 • 54 citations

Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC protocol 18781)

1993 • 53 citations

Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma

1992 • 47 citations

Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.

1994 • 47 citations

Increased Survival of Patients Treated With a Vaccinia Melanoma Oncolysate Vaccine

1997 • 47 citations

ADJUVANT BCG IMMUNOTHERAPY FOR MALIGNANT MELANOMA?

1983 • 45 citations

Broadened Clinical Utility of Gene Gun-Mediated, Granulocyte-Macrophage Colony-Stimulating Factor cDNA-Based Tumor Cell Vaccines as Demonstrated with a Mouse Myeloma Model

1998 • 44 citations

Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes

1996 • 42 citations

Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma.

1998 • 39 citations

Evaluation of Vaccinia Viral Lysates as Therapeutic Vaccines in the Treatment of Melanomaa

1993 • 39 citations

Adoptive Immunotherapy of Cancer with Activated Lymph Node Cells Primed In Vivo with Autologous Tumor Cells Transduced with the GM-CSF Gene University of Michigan, Ann Arbor, Michigan

1996 • 33 citations

Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.

1984 • 31 citations

A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma

1992 • 30 citations

Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG

1987 • 25 citations

Update on active specific immunotherapy with melanoma vaccines

1997 • 25 citations

TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.

1997 • 24 citations

Adjuvant Therapy for Malignant Melanoma

1981 • 23 citations

Generation of Therapeutic T-Lymphocytes After In Vivo Tumor Transfection with an Allogeneic Class I Major Histocompatibility Complex Gene

1995 • 22 citations

Surgical Adjuvant Therapy for Malignant Melanoma

1981 • 16 citations

Melanoma Vaccines

1994 • 15 citations

D.N.C.B. for malignant melanoma: significance in the treatment strategy.

1989 • 13 citations

Dinitrophenyl-Modified Autologous Melanoma Vaccine Induces a T Cell Response to Hapten-Modified, Melanoma Peptides

1997 • 8 citations

Immunobiologic Effects of Cytokine Gene Transfer of the B16-BL6 Melanoma

1993 • 7 citations

Immunosurgical approach to the treatment of malignant melanoma using 2,4-dinitrochlorobenzene (DNCB).

1984 • 4 citations